Here are the top 10 most valuable projects in the pipeline — ranked by their net present value — as well as their estimated worldwide product sales in 2026:
- Tirzepatide (Eli Lilly) — $2.2 billion
- Inclisiran (Novartis) — $2 billion
- Efgartigimod (argenx) — $2 billion
- BMS-986165 (Bristol-Myers Squibb) — $1.8 billion
- ALN-HBV02 (Vir Biotechnology) — $1.2 billion
- Aducanumab (Biogen) — $1.6 billion
- Belantamab (GlaxoSmithKline) — $1.3 billion
- LN-144 (Iovance Biotherapeutics) — $1.5 billion
- AK002 (Allakos) — $1.2 billion
- Risdiplam (Roche) — $1.4 billion
More articles on pharmacy:
NIH updates remdesivir treatment guidelines
J&J to start human trials for COVID-19 vaccine this week
CVS fined for understaffing, prescription errors in Oklahoma
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
